Baxter International Inc. and the Securities Class Action Lawsuit
Baxter International Inc. (NYSE: BAX) is currently under scrutiny as a shareholder initiates a securities fraud class action lawsuit. This legal action represents a significant moment for investors who purchased or acquired the company’s stock within a specific timeframe. According to reports, the lawsuit alleges that Baxter misrepresented the safety of one of its prominent medical devices, the Novum IQ Large Volume Pump.
The Allegations Against Baxter International
The lawsuit claims that Baxter portrayed its Novum IQ Large Volume Pump as a safe device for administering intravenous fluids. However, the lawsuit suggests that the company concealed critical systemic issues that could result in severe injuries to patients, even fatalities. The information being brought forward has raised many alarms among investors and stakeholders alike.
Understanding the Class Actions for Shareholders
Shareholders must ask themselves whether they meet three essential criteria to join the class action:
- Do you currently own or have you owned shares of Baxter International Inc. (NYSE: BAX)?
- Did you acquire these shares between February 23, 2022, and July 30, 2025?
- Have you experienced a monetary loss due to your investment in Baxter International?
If you answer 'yes' to all questions, it may be worth exploring your legal rights regarding this situation.
What Are Your Rights as an Investor?
If you have purchased or obtained common stock of Baxter, you are encouraged to learn more about how this legal action could affect you. This class action is focused on potential misrepresentations that could impact the investment outcomes for many shareholders. Joining involves filing necessary paperwork by the designated deadline.
Steps for Participation in the Lawsuit
To participate as a lead plaintiff in this class action, interested parties must complete the required filing by December 15, 2025. Serving as a lead plaintiff can empower you to represent the class in court, guiding the litigation process. However, it is equally important to note that you can still be part of the class without taking an active role in leading the legal proceedings.
Fees and Contingency Basis
It should be reassuring for shareholders to know that all legal representation in this case operates on a contingency fee basis, meaning that shareholders do not incur upfront costs or additional fees unless a settlement or judgment favors them.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP, established in 1993, has successfully recovered over $3.5 billion for its clients. The firm has built a reputation for effectively advocating for investors and represents a significant number of public and private pension funds across the country. Their extensive experience in litigation has led to recognition in various industry listings, underscoring their commitment to justice.
Contact for More Information
For more details, shareholders are advised to reach out to:
Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
(212) 951-2030
pallocco@bernlieb.com
Frequently Asked Questions
What does the lawsuit against Baxter International involve?
The lawsuit addresses alleged misrepresentations about the safety of Baxter's Novum IQ Large Volume Pump, impacting investor trust.
Who can join the class action lawsuit?
Investors who owned Baxter shares between February 23, 2022, and July 30, 2025, and experienced financial loss may be eligible to join.
Are there any costs associated with the lawsuit for shareholders?
No upfront fees are required; representation is contingent on the case's success.
What should shareholders do if they want to join?
They should complete the necessary filings before the deadline of December 15, 2025.
Who represents the shareholders in this case?
The class action is led by Bernstein Liebhard LLP, known for its extensive experience in class-action lawsuits.
